New biomarker identifies uveal melanoma patients at high risk for metastasis

A biomarker that puts patients at a higher risk for metastasis of uveal melanoma has been identified by researchers. Among uveal melanomas categorized as class 1, those with high levels of the biomarker PRAME mRNA were more likely to metastasize than those with low levels of PRAME mRNA, indicating that patients with this biomarker be monitored more closely for metastatic disease. (Mehr in: Cancer News — ScienceDaily)